Carregant...
Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?
Recent small-scale clinical trials have shown promising results in the use of hydroxychloroquine, an FDA approved anti-malaria drug, for the treatment of COVID-19. However, large scale, randomized and double-blind clinical trials are needed to confirm the safety and efficacy of hydroxychloroquine in...
Guardat en:
| Publicat a: | Front Immunol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7426511/ https://ncbi.nlm.nih.gov/pubmed/32849658 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.01969 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|